Summary
This 8-K filing from Edwards Lifesciences Corporation (EW), dated January 16, 2004, announces the conclusion of a dispute resolution proceeding with Baxter International Inc. The disagreement stemmed from Edwards Lifesciences' spin-off from Baxter in April 2000. The details of this resolution are not fully disclosed in the 8-K itself but are referenced in an attached press release (Exhibit 99.1). For investors, this filing signals the resolution of a potentially significant legal or financial dispute that originated at the time of the company's separation from its former parent. The conclusion of such disputes typically removes uncertainty and potential liabilities, which can be viewed positively by the market. Investors should refer to the accompanying press release for more specific details on the terms of the resolution and its potential financial implications.
Key Highlights
- 1Edwards Lifesciences Corporation (EW) announced the resolution of a dispute with Baxter International Inc.
- 2The dispute originated from Edwards Lifesciences' spin-off from Baxter in April 2000.
- 3The filing indicates the conclusion of a formal dispute resolution proceeding.
- 4A press release dated January 16, 2004, contains further details and is attached as Exhibit 99.1.
- 5The resolution of this dispute removes a point of uncertainty for the company.
- 6The Chief Financial Officer and Treasurer, Corinne H. Lyle, signed the report.